Tpg Gp A, Llc Sells 202,368 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) major shareholder Tpg Gp A, Llc sold 202,368 shares of CeriBell stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $20.12, for a total transaction of $4,071,644.16. Following the sale, the insider owned 3,765,054 shares of the company’s stock, valued at approximately $75,752,886.48. This represents a 5.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

CeriBell Price Performance

Shares of CBLL stock opened at $20.00 on Thursday. The firm’s 50 day moving average price is $18.84 and its two-hundred day moving average price is $19.73. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.01 and a current ratio of 10.44. CeriBell, Inc. has a 52-week low of $10.85 and a 52-week high of $24.33. The stock has a market cap of $758.86 million, a PE ratio of -12.27 and a beta of 0.84.

CeriBell (NASDAQ:CBLL) last issued its earnings results on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.13). CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. The business had revenue of $26.49 million for the quarter, compared to the consensus estimate of $26.09 million. As a group, analysts forecast that CeriBell, Inc. will post -1.69 EPS for the current year.

Wall Street Analysts Forecast Growth

CBLL has been the subject of a number of recent analyst reports. Weiss Ratings raised CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. Canaccord Genuity Group decreased their price objective on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a report on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, CeriBell has a consensus rating of “Moderate Buy” and an average price target of $22.20.

Hedge Funds Weigh In On CeriBell

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in shares of CeriBell by 11.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock valued at $16,935,000 after purchasing an additional 147,013 shares during the period. KCM Capital Inc boosted its position in shares of CeriBell by 40.0% during the first quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock worth $25,662,000 after buying an additional 400,000 shares during the period. Yu Fan grew its holdings in shares of CeriBell by 10.7% during the second quarter. Yu Fan now owns 1,353,166 shares of the company’s stock worth $25,345,000 after buying an additional 130,964 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of CeriBell by 1,945.9% during the fourth quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock worth $26,797,000 after buying an additional 1,162,200 shares in the last quarter. Finally, Novo Holdings A S raised its position in CeriBell by 2.3% in the 2nd quarter. Novo Holdings A S now owns 900,000 shares of the company’s stock valued at $16,857,000 after buying an additional 20,000 shares during the last quarter.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.